Business Wire

At ELECTRONICA, ITEN Present an Autonomous Asset Monitoring Solution Based on a 100µA.h Micro-Battery!

10.11.2022 18:55:00 EET | Business Wire | Press release

Share

ITEN, the deep tech company, which just closed a financing round of 80M€ to become a key player in the manufacture of solid-state lithium-ion micro-batteries, shall take the opportunity of next ELECTRONICA exhibition to present a breakthrough in the way of powering autonomous embedded systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110005719/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ecofriendly and powerful soli-state micro-battery able to recharge in a few minutes. (Photo: ITEN)

When observing the battery-powered electronic solutions, ITEN came indeed to the following conclusions:

- A lot of electronic designs relies on very polluting coin cells, difficult to assemble on Printed Circuit Boards, costly to recycle and requiring periodic maintenance to replace the battery once empty.
- Depending on the countries, only 30 to 50% of such coin cells are effectively recycled.
- Autonomous embedded systems require less and less energy to operate; however, from time to time, the power supply must deliver high current pulses for instance to drive RF transceivers or actuators; therefore, most electronic designers must use oversized coin cells because such batteries are known to deliver only small currents.

From a battery standpoint, this means that a lower battery capacity could be used if the battery would be able to deliver the required power and could be recharged regularly.

This is precisely what ITEN shall demonstrate during ELECTRONICA: ITEN shall indeed present an autonomous asset monitoring solution, including sensors and a Bluetooth Low Energy (BLE) System-on-a-chip, and powered by the combination of an indoor photovoltaic cell from DRACULA Technologies (LAYERR Technology) and ITEN’s powerful rechargeable SMD micro-battery of only 100µA.h. The solution operating 24/7 can send data every 10 seconds during the day and every 4 to 5 minutes during the night (this frequency could be increased if using a 250µA.h micro-battery instead). By comparison, a coin cell of at least 100mA.h would be required to get the same operating conditions but with a limited lifetime.

By extension, similar designs could be used in applications like BLE asset tracking, BLE tags, beacons, and sensor data loggers.

On stand B4-120, ITEN shall also demo micro-batteries used as a back-up power supply to keep some clocks or microcontrollers active or to send maintenance alerts in case of failure of the main power source.

By doing so, ITEN clearly reassert their strategy to progressively replace most of the coin cells used worldwide by ecofriendly rechargeable SMD micro-batteries containing neither heavy metals, nor toxic materials, nor organic solvents and showing a carbon footprint 200 to 1000 times less compared to coin cells.

After 8 years of R&D, ITEN have been granted more than 200 patents worldwide. ITEN are an integrated device manufacturer, controlling the complete production chain from nanomaterial synthesis up to the battery packaging and test. Even with low capacities, ITEN micro-batteries can deliver power and high current pulses. They are a concrete response to electronics designers looking for ecofriendly alternatives to coin cells. In this respect, ITEN solutions fit in with the European Directive recommending getting rid of non-rechargeable batteries in all electronic system designs from year 2030.

About ITEN:
ITEN is the leading company developing and manufacturing ecofriendly solid-state lithium-ion SMD micro batteries. Such micro batteries are rechargeable In a few minutes and can deliver power over a wide operating temperature range. They are used in many applications as back-up power supply, or to power autonomous sensor nodes or in applications like tracking and monitoring, smartphone peripherals, smart cards, medical devices, home and building automation, smart cities, wearables, and e-textiles.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

sales@iten.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 13:45:00 EET | Press release

TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its dealer network, aftersales capabilities and customer support infrastructure across key markets. In Italy, its first European market, TVS now works with around 100 dealers. Retail sales in Italy are up 110% this year to Septem

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release

Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release

WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release

Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye